Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Chul
C
Kim
Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland.
Vinay
V
Prasad
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval / Q000379:methods*; D023381:Endpoint Determination; D005500:Follow-Up Studies; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents